Since P-gp efflux restricts docetaxel entry into the brain for cancer treatment, folic acid-modified SLNs were developed to deliver docetaxel and ketoconazole (P-gp inhibitor) for brain targeting [69]. The gene discussed is PGP; the disease is cancer.